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Summary
Common variable immunodeficiency (CVID) represents a heterogeneous 
group of rare disorders. There is considerable morbidity and mortality as 
a result of non-infectious complications, and this presents clinicians with 
management challenges. Clinical guidelines to support the management 
of CVID are urgently required. The UK Primary Immunodeficiency Net-
work and the British Society for Immunology funded a joint project to 
address this. A modified Delphi Survey was conducted for the assessment, 
diagnosis and treatment of the non-infectious blood, respiratory, gut and 
liver complications of CVID. A steering group of 10 consultant immu-
nologists and one nurse specialist developed and reviewed the survey 
statements and agreed the final recommendations. In total, 22 recom-
mendations and three areas for research were developed.
Keywords: common variable immunodeficiency, complications, antibody 
deficiency, hypogammaglobulinaemia
Introduction
Common variable immunodeficiency (CVID) represents a 
heterogeneous group of rare disorders, with prevalence rang-
ing from 1 in 10 000 to 1 in 50 000 in different populations 
[1,2]. CVID is characterized by hypogammaglobulinaemia, 
defective specific antibody production and increased sus-
ceptibility to recurrent bacterial infections [2–4]. In addition 
to the increased risk of recurrent infections, patients with 
CVID are also at greater risk of autoimmune disorders and 
cancer [1,5,6]. Immunoglobulin replacement is the main 
treatment for the prevention of recurrent infections; however, 
there is little evidence regarding treatment options for the 
non-infective complications of CVID [3,7,8].
There is considerable morbidity and mortality as a result 
of non-infectious complications, and this presents clinicians 
with management challenges. Further clinical guidelines to 
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support the management of CVID are urgently required. 
The UK Primary Immunodeficiency Network and the British 
Society for Immunology funded a joint project, facilitated 
by the National Guidelines Centre (NGC), to address this. 
A comprehensive search of the literature undertaken by the 
NGC revealed little evidence or clinical guidance on the 
management of other non-infectious complications of CVID. 
The lack of evidence reflects the challenges posed in CVID 
and other rare diseases, where meaningful randomized con-
trolled studies are extremely difficult to conduct.
The published evidence available to date did not sup-
port the development of a formal evidence-based guideline 
in this area, so a Delphi consensus process (anonymous, 
multi-round, consensus building technique) was adopted 
to address the assessment, diagnosis and treatment of the 
non-infectious blood, respiratory, gut and liver complica-
tions of CVID. The Delphi method was developed in the 
1950s, and has been used successfully for generating, ana-
lysing and synthesizing an expert view to reach a group 
consensus position. The Delphi process relies upon a group 
of experts (in this case, all consultant immunologists and 
specialist immunology nurses in the United Kingdom were 
invited to participate) responding to and providing critical 
feedback on two or more consecutive surveys (in this case, 
a set of statements regarding the management of non-
infectious complications of CVID). The initial statements 
were developed by a steering group of 10 consultant 
immunologists and a nurse specialist. Following the Delphi 
principles, the initial recommendations that had not met 
consensus after the first round of the survey were modi-
fied according to the expert feedback and recirculated to 
the expert group. The recommendations that achieved 
consensus group are described in the Results section of 
this paper. The group were aware of the consensus state-
ment on granulomatous–lymphocytic interstitial lung dis-
ease (GLILD) [9] and therefore did not repeat this work.
Methods
Delphi methods
Development of consensus statements. The steering group 
met and identified the non-infectious complications and the 
areas of management to be included within the survey. The 
steering group agreed to focus on non-infectious blood, 
respiratory, gastrointestinal (GI) and liver complications as 
the most commonly encountered complications where there 
is little evidence to guide practice. The steering group 
formulated and validated the consensus statements at each 
round for the survey. The statements were revised if further 
clarification was required and sent back to the expert group 
until no further clarification was needed.
Responses were graded on a four-point Likert scale: 
‘strongly agree’, ‘agree’, ‘disagree’ and ‘strongly disagree’, 
with an option of ‘I don’t have the expertise’.  A threshold 
of 70% to agree (strongly agree or agree) or disagree 
(strongly disagree or disagree) was used to evaluate the 
responses. This threshold is routinely used in Delphi pro-
cesses as a recognized measure of consensus, and state-
ments reaching this threshold were noted to be agreed 
and not included in subsequent rounds [10]. Free text 
boxes were included in the survey after each section to 
give respondents the opportunity to comment on or clarify 
the statements or responses. These comments were taken 
into account when revising the statements that did not 
meet consensus. There is no complete agreement about 
the termination of a Delphi process, and when no clear 
indication was given on how to amend a statement from 
the expert group this was removed from the survey.
The expert group for the survey was identified from 
the Royal College of Physicians (RCP) 2016 consultant 
census of immunologists. The aim was to target all the 
consultants practising in clinical immunology adult services 
in the United Kingdom. The census identified 85 consult-
ants, in addition to the members of the steering group. 
The steering group did not participate in the Delphi 
Survey. The RCP sent out invitation e-mails and two 
reminders for each round of the Delphi survey. E-mails 
were sent to each identified consultant outlining the aim 
of the survey, giving instructions and a link to the survey. 
Nurse specialists were also invited to take part. The nurse 
specialists were identified from the Immunology and 
Allergy Nurses group, 75 of whom identify as immunol-
ogy specialist nurses. The survey questionnaire was sent 
to all members of the expert group via SurveyGizmo 
software. Responses remained anonymous.  The whole 
process was conducted online, with an 8-week cycle time 
between rounds. This allowed for the questionnaire invi-
tation to be sent, for two reminders to be sent to par-
ticipants for completion and for the analysis to be 
conducted prior to the next sequential round.
The steering committee formulated recommendations 
based on the consensus statements. The steering commit-
tee reviewed all free text comments from the responders 




The steering group that developed the questionnaire con-
sisted of a facilitator from the NGC, 10 consultant immu-
nologists and one nurse specialist.
Thirty-nine participants from 21 immunodeficiency 
services (of a total of 34 adult UK immunodeficiency 
services) took part in the first round of the survey; 35 
of 85 (41%) consultants and four of 75 (5%) nurse 
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specialists. The first-round survey was completed by 33 
of the 39 participants, while six participants only partially 
completed the survey. More than 70% of the participants 
had worked in immunology as a speciality for more 
than 10 years, and each had direct involvement with 
more than 50 patients with CVID. Twenty-two partici-
pants, all of them consultants, from 16 immunodeficiency 
centres completed the second round of the survey. More 
than 80% of the participants had worked in immunology 
as a speciality for more than 10 years and 50% have 
direct involvement with more than 50 patients with 
CVID.
Of the 63 statements in the first round, 57 achieved 
consensus. For details of the statements that did not reach 
consensus see Appendix 1. Of the remaining six state-
ments, two still did not achieve consensus in the second 
round. The steering group made the decision not to make 
recommendations based on the two statements that did 
not reach consensus. The statements that achieved con-
sensus were reviewed by groups representing patients with 
CVID, and their comments have been incorporated into 
the discussions below.
Summary of recommendations
The recommendations should be considered in the context 
of the individual needs of the adult with CVID.
Baseline assessment and monitoring for non-infectious 
complications
Although not all people with CVID develop complica-
tions, close attention to monitoring is required to identify 
any complications at an early stage. It is not yet pos-
sible to confidently predict the subsets of people at 
high risk.
Recommendation 1. Adults with CVID should:
• be weighed at least 6-monthly
• have a clinical examination of their lymph nodes at 
least annually to monitor for the development of 
persistent lymphadenopathy
• have a clinical examination of their abdomen at least 
annually to monitor for the development of 
hepatosplenomegaly
• have a full blood count taken 6-monthly to monitor 
for the development of autoimmune cytopaenias
• have blood tests for B12, folate and ferritin in the 
presence of anaemia, malabsorption or neuropathy
• have liver function tests (LFTs) assessed 6-monthly 
to monitor for the development of hepatitis
• have full pulmonary function tests including transfer 
factor at least every 3 years to monitor for the devel-
opment of interstitial lung disease
• have a baseline high resolution CT (HRCT) chest to ex-
clude bronchiectasis and lymphadenopathy/other pa-
thology. If a HRCT chest has been performed in the last 
12 months, this can be used as the baseline assessment:
◦ a baseline HRCT chest should include the upper 
abdominal viscera to assess lymphadenopathy, 
spleen size and hepatobiliary architecture unless 
an abdominal ultrasound has been performed in 
the last 12 months to assess the liver and spleen.
Eighteen per cent (n = 7) of respondents suggested that 
full pulmonary function testing was performed annually 
for all patients in their practice. Recommendation 8 increases 
the frequency of pulmonary function testing to annually 
in CVID patients who are found to have splenomegaly.
Multi-professional care
Recommendation 2. Adults with non-infectious complica-
tions of CVID should be managed as part of a multi-
professional team that includes an appropriate organ-based 
specialist with an interest in primary immunodeficiency.
Haematological complications
Recommendation 3. Where an autoimmune cytopenia is 
suspected:
• a clinical assessment for other secondary causes should 
be undertaken (for example, drugs, hypersplenism or 
lymphoproliferative disease)
• a blood film should be a first-line investigation to 
help identify the underlying cause
• antibody testing (for example, for anti-granulocyte, 
anti-platelet) should not be performed routinely
Recommendation 4. Immunology centres should agree 
monitoring, action or referral thresholds for adults with 
CVID and features of haematological complications with 
the local haematology team.
Recommendation 5. Adults with autoimmune haemo-
lytic anaemia should be treated according to the British 
Society for Haematology Guidelines on the management 
of drug-induced immune and secondary autoimmune 
haemolytic anaemia [11].
Respiratory complications
There is an overlap between infectious and non-infectious 
respiratory complications of CVID. For this reason, the 
Steering Group decided to include statements regarding 
identification and management of bronchiectasis. The 
management of upper respiratory tract infections is not 
addressed in this guideline.
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Recommendation 6. Adults with CVID and ongoing 
frequent respiratory tract infections should have a HRCT 
chest at least every 5 years to monitor for the develop-
ment of bronchiectasis.
Recommendation 7. Adults with CVID and bronchi-
ectasis and ongoing frequent respiratory tract infections 
should have a HRCT chest at least every 5 years to moni-
tor the progression of bronchiectasis.
Recommendation 8. Adults with CVID and spleno-
megaly should have annual pulmonary function tests (PFT) 
including transfer factor to monitor for the development 
of interstitial lung disease.
Recommendation 9. Centres should agree monitoring, 
action or referral thresholds for adults with CVID with 
features of respiratory complications with the local 
Respiratory team.
Recommendation 10. Adults with CVID and bronchi-
ectasis should be managed jointly with a consultant chest 
physician and an immunologist.
In the free text section, all the respondents stressed 
the importance of using clinical judgement and individual 
patient assessment to determine the exact frequency of 
computerized tomography (CT) scanning and pulmonary 
function tests (PFT). It is acknowledged that in some 
cases more frequent scanning or PFT may be indicated. 
The radiation risk associated with CT scanning was high-
lighted by respondents commenting that some patients 
with CVID may be particularly radiosensitive, and thus 
potentially more susceptible to ionizing radiation. The role 
of PFT in place of, and as an adjunct to, HRCT was 
emphasized by several respondents in order to minimize 
radiation exposure. The committee concluded that alterna-
tives such as low-dose HRCT and magnetic resonance 
imaging (MRI) may also be considered.
GI complications
Infectious diarrhoea is the most common GI complication 
in CVID [12], while 9–15% of patients are reported to 
develop non-infectious GI complications [8,13]. Diagnosis 
of non-infectious GI complications requires that infection 
is excluded as a cause of symptoms. As a result, the steer-
ing group agreed to include statements relating to infection 
in the Delphi survey, even though infectious complications 
are not the main focus of these guidelines.
Recommendation 11. Adults with CVID and evidence of 




• fat soluble vitamins
Respondents highlighted that malabsorption should be 
considered in patients with unexplained weight loss.
Adults with CVID and Helicobacter pylori 
Recommendation 12. Adults with CVID and H. pylori 
should be offered eradication in line with National Institute 
for Health and Care Excellence (NICE) guideline CG184 
(Gastro-oesophageal reflux disease and dyspepsia in adults: 
investigation and management) [14].
Adults with CVID and diarrhoea
Recommendation 13. In adults with CVID and diarrhoea 
for more than 2 weeks the following infections should 
be excluded:
• Campylobacter 








• Other intestinal parasites (for example, isospora)
In the free text section, a number of respondents favoured 
a stepwise approach, with first-line investigations to exclude 
Campylobacter , C. difficile toxin, Giardia , Salmonella and 
Shigella , only proceeding to investigating for viruses, 
mycobacteria and other parasites if these first-line tests 
are negative.
Recommendation 14. Adults with CVID and non-
infectious diarrhoea or malabsorption should be referred 
to a consultant gastroenterologist and a dietician.
Recommendation 15. Where initial tests for infection 
are negative, all patients with persistent diarrhoea should 
be referred for lower GI endoscopy with biopsy for the 
assessment of:
• GLILD – including typical and atypical Crohn’s 
disease
• inflammatory bowel disease, including typical and 
atypical ulcerative colitis
• lymphocytic infiltration to suggest autoimmune 
enteropathy
• lymphoma (T and B cell)
• infection [CMV, enteroviruses, Epstein–Barr virus 
(EBV)]
Recommendation 16. Where initial tests for infection are 
negative, all patients with persistent diarrhoea should be 
referred for upper GI endoscopy with biopsy for the 
assessment of:
• coeliac and coeliac-like enteropathy
• lymphocytic infiltration to suggest autoimmune 
enteropathy
C. Bethune et al.
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• small bowel biopsy and jejunal aspirates to exclude 
giardia
• lymphoma (T and B cells)
• infection (CMV, enteroviruses)
• nodular lymphoid hyperplasia
Recommendation 17. Centres should agree a protocol with 
the local gastroenterology team to guide observations and 
indicate the pathological samples to be taken at endoscopy 
in adults with CVID.
The consensus was clear that both upper and lower GI 
endoscopies should be examined to exclude lymphoma, 
and respondents emphasized the importance of working 
closely with histopathologists and gastroenterologists.  The 
respondents recognized the lack of evidence regarding the 
underlying reasons for the increased risk of malignancy in 
CVID, but there was clear consensus for the need to exclude 
malignancy in this clinical context. Both rounds of the 
survey included statements which included specific methods 
for identification of viruses and CD4 and CD8 T cells in 
gastrointestinal biopsies, and these all received high levels 
of agreement. However, the expert group felt that these 
were too restrictive, and that the intent of the recommen-
dations was to highlight the need to exclude specific infec-
tions and lymphoma without limiting the methodologies 
used. The statements were condensed to reflect this.
Consensus was not reached regarding examination of 
stool samples for EBV and AAFB; however, it was recom-
mended that if biopsies are taken EBV should be excluded.
Recommendations for adults with CVID and 
pernicious anaemia
Recommendation 18. Adults with CVID and pernicious 
anaemia should have:
• an upper GI endoscopy performed within 6 months of 
diagnosis
• monitoring arranged according to local gastroenterol-
ogy guidance
Recommendations for adults with CVID and coeliac 
disease
Recommendation 19. Adults with CVID and coeliac disease 
should have:
• an upper GI endoscopy and biopsies performed prior 
to gluten avoidance
• an upper GI endoscopy and biopsies performed after 
6 months on a gluten-free diet to assess response
• monitoring arranged according to local gastroenterol-
ogy guidance
The steering group acknowledge the difficulty in diagnos-
ing coeliac disease in patients with CVID in whom the 
serological tests are not useful. The existence of non-gluten 
sensitive enteropathy histologically similar to coeliac disease 
is also recognized [15]. Comments from the survey high-
lighted the possibility of using human leucocyte antigen 
(HLA)-DQ2/8 testing to identify patients in whom coeliac 
disease is unlikely.
Hepatobiliary complications
Recommendations for adults with CVID and abnormal 
liver function tests (LFTs)
Recommendation 20. Adults with CVID and abnormal 
LFTs should have:
• LFTs repeated to avoid unnecessary additional 
investigations
• their drugs reviewed for hepatotoxicity
• advice to avoid alcohol until they have been seen by a 
hepatologist
Recommendation 21. Centres should agree monitoring, 
action or referral thresholds for people with CVID and 
abnormal LFTs with the local hepatology team.
Recommendation 22. Assess for granulomatous disease 
and autoimmune disease in other organs in adults with 
CVID and associated liver disease.
Discussion
This is the first set of UK recommendations for the moni-
toring and management of non-infectious complications 
of CVID. We used the Delphi method to produce several 
consensus statements. This method was chosen as there 
is not a sufficiently large evidence base for the diagnosis 
and management of any of these complications on which 
to develop evidence-based guidelines, as is often the case 
with rare diseases. We started with 63 statements; 59 
statements reached consensus and were condensed into 
22 recommendations.
The steering group identified a number of significant 
non-infectious complications of CVID to address in the 
Delphi statements. There is an inevitable overlap with 
infectious disease, particularly where exclusion of infection 
is critical to the diagnosis of non-infectious complications. 
As a result, some statements regarding infectious com-
plications had to be included. GLILD was not addressed, 
as a UK consensus statement on the management of 
GLILD has recently been published [9].
The increased risk of malignancy in this group of patients 
is acknowledged; the statements recommending for regular 
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clinical assessment (including weight) and regular moni-
toring blood tests were included to take this into account. 
Development of further guideline/consensus on screening 
and monitoring for cancers such as gastric cancer and 
lymphomas will be required in the future.
The survey respondents were representative of medical 
consultants specializing in immunology working in the 
United Kingdom, although there was a low response rate 
from the nurses’ group. Overall, the majority of partici-
pants (80%) had more than 10 years’ experience in immu-
nology, cared for 50 or more CVID patients (70%) and 
worked in 21 of the 36 immunodeficiency centres in the 
United Kingdom. Fifty-two per cent (n = 44) of the cur-
rent consultant immunologist workforce contributed to 
developing these recommendations, including the members 
of the steering group.
In all the areas of the survey, respondents emphasized 
the importance of the multi-disciplinary team approach 
for the management of patients, including expert histo-
pathologists where appropriate. This is line with the recently 
published guideline on GLILD, another non-infectious 
complication of CVID [9]. The steering group acknowl-
edges that individual patient management should also take 
into account other co-morbidities and the presence of 
other manifestation/complications of CVID, and should 
be in accordance with the patient’s needs.
The survey was sent to immunologists, and not the 
organ-based specialists who are also involved in the care 
of these patients. This was due to the difficulty in iden-
tifying organ-based specialists with sufficient expertise and 
is a limitation of this work. However, recent UK census 
data show that 50% of immunology services in the United 
Kingdom hold combined respiratory/immunodeficiency 
clinics and 25% combined gastroenterology/immunodefi-
ciency clinics (data from 2017 UK Primary 
Immunodeficiency Network/Royal College of Physicians 
Quality in Primary Immunodeficiency Services census). 
It is therefore probable that the responses are likely to 
be congruent with recommended practice in these multi-
disciplinary team (MDT) settings.
The steering group recognizes the flaws of the Delphi 
method, including the arbitrarily set level of consensus, the 
risk of bias when responding to feedback from participants 
and the difficulties when administrating the Delphi elec-
tronically [16]. Despite these, the Delphi method is useful 
for establishing consensus in rare disease management.
We hope that this guideline will be widely adopted 
and will be used by centres caring for CVID patients 
in the United Kingdom in order to compare their cur-
rent practices with these recommendations. It will also 
raise further research questions and encourage audit 
and collaboration to address the uncertainties in several 
areas.
Lessons learnt
Establishing a Delphi consensus in rare diseases with few 
specialists can be challenging when 20% of the available 
medical respondents comprise the steering group.
In total, 44 consultant immunologists and four specialist 
nurses were involved in developing these recommenda-
tions. It is reassuring that a high level of consensus was 
reached in the first round, suggesting a good degree of 
nationwide consensus among respondents, even in the 
absence of high-quality evidence or previous guidelines.
Strategies to improve input organ-based specialists with 
relevant experience in pelvic inflammatory disease (PID) 
complications should be developed in future.
Responses from the nursing group were much lower: 
this may reflect a perceived lack of expertise in the diag-
nosis and medical management of the CVID complications 
described.
We cannot presuppose the reasons for non-responses 
as the reasons for not completing an online survey will 
vary, and it is possible that agreed single individuals may 
have responded on behalf of larger centres). However, it 
will be important to explore ways to optimize response 
rates with the Delphi process for future surveys. This 
process has emphasized the need to promote awareness 
of these complications and provide guidance on their 
identification and management.
Areas for research
The steering group identified the following areas for future 
research.
1. Better description of the natural history of progression 
of non-infectious complications and combinations of 
these patient cohorts. This will help identification and 
early intervention where appropriate. Next-generation 
sequencing may help to categorize subgroups with 
predisposition for certain complications within the 
CVID cohort.
2. Improved identification of risk factors for these compli-
cations, including demographics, family history, con-
current diagnoses and genetics. This may eventually 
lead to pre-emptive treatment, including targeted thera-
pies, gene therapy and stem cell transplantation.
3. Increased collection of prospective data with regard to 
specific complications of CVID. The study of interstitial 
lung disease in primary antibody deficiency [17] is an 
example of this. Similar initiatives are therefore urgently 
needed to improve treatment outcomes for other life-
limiting complications of CVID. This will require co-
ordinated and sustained efforts of the whole immunology 
community to support such prospective studies.
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Conclusions
We present the first set of UK recommendations for the 
monitoring and management of non-infectious complica-
tion of CVID. This will help to standardize practices and 
facilitate future audit, quality improvement work and 
research for this cohort of patients.
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APPENDIX 1
Statements that did not achieve consensus in the 
first round.
Free text comments from the survey regarding 
statements that did not reach consensus
Annual ultrasound monitoring for hepatosplenomegaly 
In the first round the comments supported an annual 
clinical examination, agreeing that this was important for 
monitoring for hepatosplenomegaly and lymphadenopathy, 
but noted that an annual ultrasound was unnecessary if 
there was no clinical suspicion of organomegaly. This added 
another appointment for the patient and is not useful in 
directing clinical management. The respondents commented 
that the frequency of an ultrasound should be guided by 
clinical findings and not for monitoring. One respondent 
highlighted that clinical examination for hepatospleno-
megaly is not sufficiently sensitive except for major organ 
enlargement. This steering group agreed that a revised 
statement about clinical examination was more appropriate 
and was included in the subsequent Delphi round.
Annual screening for  H. pylori
In the first round the comments strongly agreed that 
the routine screening of H. pylori was unnecessary, and 
the value of doing this was unclear. The steering group 
agreed to amend the focus of the recommendation to adults 
with CVID and H. pylori and to direct clinicians to the 
NICE guideline for details on H. pylori eradication. This 
recommendation was moved from the monitoring section 
to the gastrointestinal (GI) complications section.
Blood tests for GI complications 
In the first round, the comments noted that blood tests 
used in monitoring could be performed as markers for 
other conditions, such as malabsorption and neuropathy, 
and not simply anaemia. The steering group re-phrased 
the statement to ‘Adults should have blood tests for B12, 
folate and ferritin in the presence of anaemia, malabsorp-
tion or neuropathy’. In the second Delphi survey round 
this statement reached 90% consensus strongly agree/agree. 
This recommendation was moved from the monitoring 
section to the GI complications section.
Excluding HIV, EBV, AAFB in patients with persistent 
diarrhoea 
No consensus was achieved on screening for HIV, EBV 
or AAFB in patients with diarrhoea. The steering group 
rephrased this statement to ‘if diarrhoea is prolonged 
and no other cause has been identified consider testing 
for HIV, EBV and AAFB’. Consensus was only achieved 
for HIV screening (85%) in the second round and was 
included in the recommendation for assessment on biopsy 
when a patient has persistent diarrhoea. Consensus was 
not reached for EBV and AAFB assessment (63 and 
68.5%) in the second Delphi round and the steering group 
agreed to exclude these assessments from the recommen-
dations. The comments from respondents for these two 
pathogens predominantly referred to their likelihood of 
being unusual causes of diarrhoea in the setting of CVID, 
and therefore should not be part of first line 
investigations.
Additional statement added in the second round 
This statement, ‘adults with CVID and malabsorption 
should be tested for the following: haematinics, calcium, 
vitamin D and fat soluble vitamins’ was added to the 
second round survey in response to comments made in 
the first Delphi round about checking for micronutrient 
deficiencies. This statement achieved consensus in the 
second round and was added to the recommendations.
Table A1. Delphi statements where consensus was not reached in the first round on the monitoring of non-infectious complications
Results %
Strongly disagree/ disagree Strongly agree/agree
Adults with CVID should have an ultrasound of upper abdomen 
performed at least annually to monitor for the development of 
hepatosplenomegaly
64 36
Adults with CVID should have annual screening for Helicobacter 
pylori 
53 47
Adults with CVID should not have blood tests for B12, folate and 
ferritin unless anaemia is present
35 65
In adults with CVID and diarrhoea for more than two weeks the 
following opportunistic infections should be excluded:
Human immunodeficiency virus (HIV) 40 60
Epstein–Barr virus (EBV) 39 61
Alcohol and acid-fast bacilli (AAFB) 43 57
CVID = common variable immunodeficiency.
